Abstract: A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17?-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.

Abstract: A pharmaceutical composition for preventing or treating female climacteric syndromes comprising Loganin which increases the concentration of estradiol (17?-estradiol, E2) in the blood of a menopausal mouse model and has shown efficacies such as an increase in the estrogen receptor alpha expression in the uterus, which remedies uterine contraction and degeneration, and decreases in the accumulation and the size of adipocytes in liver and the abdominal adipose tissues and the liver and weight loss, a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.